捷豹健康通过非稀释性资金努力减少债务、延长信贷，并推动了crofelemer的开发。 Jaguar Health reduced debt, extended credit, and advanced crofelemer development with non-dilutive funding efforts.

Jaguar Health 通过重组与芝加哥风险投资合作伙伴的债务和特许权使用费义务、减少300万美元负债、延长700万美元信贷额度三年以及取消48,212个认股权证，改善了财务状况。 Jaguar Health has improved its financial health by restructuring debt and royalty obligations with Chicago Venture Partners affiliates, reducing $3 million in liabilities, extending a $7 million credit line by three years, and eliminating 48,212 warrants. 这些子公司的债务在2026年7月之前没有到期,减轻了近期压力。 No debt from these affiliates matures before July 2026, easing near-term pressure. 该公司继续推进其稀有胃肠紊乱的骨架开发方案,由Napo制药公司根据公平贸易做法管理可持续收获。 The company continues advancing its crofelemer development program for rare gastrointestinal disorders, with sustainable harvesting managed by Napo Pharmaceuticals under fair trade practices. Jaguar正通过潜在的伙伴关系寻求非增值性资金,并期待其肠道衰竭方案中的临床里程碑。 Jaguar is pursuing non-dilutive funding through potential partnerships and expects clinical milestones in its intestinal failure program. 前瞻性说明可能存在风险。 Forward-looking statements are subject to risks.